A股異動 | 科順股份(300737.SZ)大漲8%逼近新高 2019年度淨利接近翻倍
格隆匯4月21日丨科順股份(300737.SZ)近期走勢向上,現大漲8%,報21.32元逼近歷史新高,暫成交2億元,最新總市值129.57億元。科順股份昨日公佈,2019年度淨利潤升96.13%至3.63億元,惟一季度淨利潤降29.97%。展望2020年全年,科順股份預計新冠疫情對公司及所屬行業影響有限。民生證券點評稱,隨着海南自貿區、雄安新區、西部大開發和長三角一體化為代表的國家重點規劃推進,公司將持續受益下游需求的穩定增長。當前建材行業可比公司平均估值為24倍,給予推薦評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.